P1: PSB Printer: Yet To Come
9780521704632ind CUFX213A/Peck 9780521618168 December 29, 2007 17:19
368 Indexgeneral anaesthetic agents, 99 , 134t
anatomical sites of action, 99
lipid solubility, 99 –100
mechanisms of action, 99 –102
molecular theories, 99 –100
protein sites of action, 100 –102
see alsoinhaled anaesthetics; intravenous
anaesthetics
genetic polymorphism, 19
gentamicin, 319 –320
giving sets, drug interactions, 40
glibenclamide, 348 –349
gliclazide, 348 –349
glipizide, 348 –349
globulin, drug binding, 7
glomerular filtration, 20
glucagon, 216
glucocorticoid(s), 353 –355
adrenal suppression, 354
anti-inflammatory effects, 353 –354, 355t
fluid retention, 354 –355
immunosuppressive effects, 354
metabolic effects, 353
perioperative supplementation, 355
vascular reactivity, 355
glucocorticoid receptor, 31
glucose, 87
absorption, 3
blood–brain barrier crossing, 15
insulin release, 347
see alsohypoglycaemic agents
glucuronidase, 21
glucuronidation, 18 –19
glucuronide group, 94
glutamate, 86
ionotropic, 26
ketamine antagonism, 37
glyceryl trinitrate, 249 –250
effects, 249 –250
giving set interactions, 40
kinetics, 250
mechanism of action, 249
metabolism,250f
presentation, 249
uses, 249
glycine, 86
glycine receptors, 102
glycopeptides, 322 –323
mechanism of action, 322
glycoprotein IIb/IIIa receptor antagonists, 338
glycopyrrolate, 287 , 289
blood–brain barrier crossing, 15
G-protein(s), 26 –30
cycle, 29 –30
αsubunit, 28G-protein coupled receptors (GPCRs), 26 –30
adrenaline action, 42
Graham’s law, 5
Gram-negative bacilli, 312
Gram-positive cocci, 312
guanethidine, 263 –264, 357
guanylyl cyclase, membrane, 30
gut, drugs acting on, 292 –297
antacids, 292
drugs affecting gastric motility, 295
drugs influencing gastric secretion,
293 –295
mucosal protectors, 296
prostaglandin analogues, 296 –297haemodialysisseecontinuous veno-venous
haemodiafiltration (CVVHDF)
haemostasis, 336
half-life, 74
natural logarithms, 58 –59
terminal elimination, 71
halogen group, 94
halothane, 114 , 124, 126t
effects, 124
metabolism, 124
toxicity, 124 , 126t
Hartmann’s solution, 300 , 302t
heart valves, artificial, medication during
pregnancy, 16
helium,132t
Henderson–Hasselbalch equation,5–6
heparins
actions,340f
low molecular weight, 341 –342
therapy monitoring, 342
therapy monitoring, 342
unfractionated, 340 –341
kinetics, 341
mechanism of action, 340
side-effects, 340 –341
uses, 340
hepatic encephalopathy, 22
hepatic enzymes
first-pass metabolism,9–10
microsomal,20t
hepatocytes, rapid uptake of drugs, 11
heterocyclic groups, 46 –47, 94
hexamethonium, 269
hexobarbitone, 102 –103
HIV infection, 334
Hofmann degradation, 18 , 90
atracurium, 189
cis-atracurium, 18 , 189–190
homovanillic acid, dopamine kinetics, 205
hormone replacement therapy, 358 –359